BioWorld: The Daily Biopharmaceutical News Source
5 days ago · Among the most profound results presented at the 2024 European Society for Medical Oncology Congress were the 10-year data from the Checkmate-067 and Keynote-006 trials of Opdivo and Keytruda as first-line agents in advanced or metastatic melanoma in which 10-year overall survival topped 40%.
BioWorld: The Daily Biopharmaceutical and Medical Technology …
These cookies are used to enable social media sharing or “like” buttons on our services. They also provide the ability to link your account or engage with our content on or through a social media platform such as Facebook, Twitter or LinkedIn.
Biopharma financings surge to $86.2B in 2024, with $8.7B in …
Oct 4, 2024 · Biopharma financings continued to outperform over the first nine months of 2024, hitting $86.2 billion, a 75% increase from the $49.35 billion raised during the same period in 2023. September alone saw a significant boost from the prior month, with financings more than doubling to $8.7 billion from $3.5 billion in August.
Interline Therapeutics divulges new RIPK2 inhibitors
Jan 5, 2024 · Interline Therapeutics Inc. has synthesized receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors reported to be useful for the treatment of cancer, inflammation, allergy, fibrosis, autoimmune, cardiovascular and metabolic diseases.
‘Evo’ AI can design complete genomes - BioWorld
Nov 18, 2024 · The development of new machine learning tools like Alphafold and Rfdiffusion has allowed scientists to predict the structure of proteins and design them for drug discovery purposes, among other uses. Now, scientists at the Arc Institute have created Evo, an AI model that generates DNA sequences and estimates their interaction with other molecules at single-nucleotide resolution, scalable to an ...
China - Articles - BioWorld
Dec 31, 2024 · Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business, financing, regulation, science, product development, clinical trials and more
JCR brings J-Brain Cargo technology to neurodegenerative
Mar 31, 2023 · JCR Pharmaceuticals Co. Ltd. has signed a research collaboration, option and license agreement with Alexion, Astrazeneca Rare Disease, part of Astrazeneca plc, to develop an undisclosed initial therapeutic molecule that applies JCR's proprietary J-Brain Cargo blood-brain barrier penetration technology for the treatment of a neurodegenerative disease.
Patents - Articles | BioWorld
Dec 31, 2024 · Merck Sharp & Dohme LLC has patented new 5,6 saturated bicyclic heterocyles acting as NLRP3 inflammasome inhibitors potentially useful for the treatment of atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune disease, Alzheimer’s and Parkinson’s disease, among others.
Nuala Moran - BioWorld
Dec 9, 2024 · BioWorld - Nuala Moran. A U.K. study has uncovered distinctive genetic drivers of type 2 diabetes in South Asians that lead to faster development of complications, the need for earlier insulin replacement therapy and a weaker response to some widely prescribed drugs.
Allianthera (Suzhou) Biopharmaceutical patents new aryl
Jun 9, 2023 · Allianthera (Suzhou) Biopharmaceutical Co. Ltd. has patented new aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of cancer, lung diseases, bone, dermatological, eye, gastrointestinal, neurological and pancreatic disorders, among others.